GO
Loading...

Pharmaceuticals

More

  • Flu drug stockpiles a waste of money: Report Thursday, 10 Apr 2014 | 6:27 AM ET

    The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.

  • PARIS/ ZURICH, April 10- France's competition authority is investigating drugmakers Roche and Novartis on suspicion they were involved in anti-competitive practices in relation to eye disease treatments, the companies said on Thursday.

  • April 10- A two-drug combination being tested by Merck& Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.

  • MUMBAI, April 9- India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a $3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.

  • MUMBAI, April 9- India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a $3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.

  • LONDON, April 9- The World Health Organisation wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.

  • Ultragenyx is now up around 150 percent from its IPO price. Its CEO Dr. Emil Kakkis provides insight on the development of its drugs, and just how committed the company is to treating patients with the diseases its drugs treat.

  • *Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly. *Award unlikely to stand after Takeda and Eli Lilly challenges. Eli Lilly and Co, Takeda's co-defendant in the case, was ordered to pay $3 billion in punitive damages by the jury in Louisiana on Monday.

  • Chief Justice John Roberts on Tuesday asked generic drug manufacturers to respond to a request from Teva Pharmaceutical Industries Ltd seeking to prevent a lower court ruling from taking effect while the high court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug, Copaxone.

  • *Working on more tiered pricing after deal with Egypt. LONDON, April 8- Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.

  • Teva launches generic version of fish oil drug Tuesday, 8 Apr 2014 | 10:47 AM ET

    NEW YORK— Teva Pharmaceutical Industries said Tuesday it is now selling a generic version of the heart medication Lovaza, which is used to treat high triglyceride levels.

  • Ahead of the Bell: Alkermes shares jump Tuesday, 8 Apr 2014 | 9:24 AM ET

    Shares of Alkermes Plc soared Tuesday before markets opened and after the Irish drugmaker said its long-lasting antipsychotic performed better than a placebo in a late-stage clinical study.

  • AP Top Extended Financial Headlines At 2:26 p.m. EDT Tuesday, 8 Apr 2014 | 9:03 AM ET

    Regulators act to require US banks to have stronger capital base to reduce financial threats IMF: World economy gains but faces too-low inflation and capital losses from emerging nations US employers posted more job openings in February, a sign that hiring will pick up EU's top court nixes snooping legislation, strengthens privacy rights Stocks rise for the time in four days; Gilead slumps on pressure over new drug Energy Department forecasts slightly lower gasoline prices for the summer and year GM investing $449 M in 2 Detroit-area plants to build next-generation Volt; more jobs expected Japan pharmaceutical company Takeda penalized over diabetes drug, plans to challenge verdict Comcast makes its case for taking over Time Warner Cable, stresses benefits in gov't filings After spike in deaths, railroads launch campaign to highlight dangers of being near tracks

  • Eli Lilly ordered to pay $3B in diabetes drug case Tuesday, 8 Apr 2014 | 7:44 AM ET

    Eli Lilly and Takeda Pharmaceutical were ordered to pay billions in damages over claims that they concealed cancer risks of its Actos diabetes drug.

  • *Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly. SAN FRANCISCO/ TOKYO, April 8- Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging that Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug.

  • US jury hits Takeda, Eli Lilly with $9B penalty Tuesday, 8 Apr 2014 | 3:33 AM ET

    TOKYO— A U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and its U.S. counterpart, Eli Lilly and Co., to pay $9 billion in punitive damages over a diabetes medicine linked to cancer. The U. S District Court in western Louisiana ordered a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly.

  • TOKYO, April 8- Japanese shares fell 1.4 percent to a two-week low on Tuesday as Takeda Pharmaceutical Co tumbled after a U.S. jury ordered it to pay $6 billion over claims it concealed risks associated with its Actos diabetes drug. During the session, the Bank of Japan stood pat on policy as expected after a two-day policy meeting.

  • Emilia Falcetti, Analyst, Japan Healthcare Equity Research at Cantor Fitzgerald, says Daiichi Sankyo's decision to sell its controlling stake in Ranbaxy will have a negative impact on its earnings.

  • April 7- Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its lucrative drug to treat multiple sclerosis, Acthar Gel.

  • Mallinckrodt buys Questcor for about $5.2 billion Monday, 7 Apr 2014 | 8:39 AM ET

    In order to diversify its business, Ireland's Mallinckrodt is buying California-based Questcor Pharmaceuticals in a deal reaching $5.2 billion.

Most Popular Video

Monday, 21 Apr 2014 | 6:34 AM ET

Rebecca Patterson, Bessemer Trust, and Barbara Reinhard, Credit Suisse, share their thoughts on the pullback in stocks and the market's reaction to comments made by the Fed's Yellen.

Monday, 21 Apr 2014 | 12:02 AM ET

Simon Grose-hodge, Head of Investment Advisory, South Asia at LGT Bank Singapore, remains overweight on developed markets as the U.S. and Europe are showing signs of recovery.

Sunday, 20 Apr 2014 | 9:42 PM ET

Caroline Russell, CEO of Boh Plantations, speaks to CNBC's Julia Wood about the company's focus on maintaining dominance in its home market of Malaysia.